These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 4054715)

  • 41. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer.
    Lund B; Hansen OP; Hansen HH; Hansen M
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):26-9. PubMed ID: 1411618
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [A phase I study of VP-16-213 (VP, etoposide) by single and 5-day intravenous administration].
    Wakui A; Yokoyama M; Takahashi H; Yoshida Y; Sakata Y; Sato S; Kano A; Kawamoto K; Hashimoto S; Konno K
    Gan To Kagaku Ryoho; 1986 Feb; 13(2):319-29. PubMed ID: 3947109
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase II study of VP 16-213 (etoposide) in metastatic transitional cell urothelial cancer.
    Ponder BA; Oliver RT
    Cancer Chemother Pharmacol; 1984; 12(1):64-5. PubMed ID: 6690078
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Doxorubicin plus VP-16-213 for the treatment of refractory breast carcinoma.
    Konits PH; Van Echo DA; Aisner J; Morris D; Wiernik PH
    Am J Clin Oncol; 1982 Oct; 5(5):515-9. PubMed ID: 6758569
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma.
    Cohen MH; Broder LE; Fossieck BE; Ihde DC; Minna JD
    Cancer Treat Rep; 1977; 61(3):489-90. PubMed ID: 194694
    [No Abstract]   [Full Text] [Related]  

  • 46. Cisplatin plus oral etoposide in the treatment of patients with advanced small cell lung cancer. Japan Clinical Oncology Group.
    Asamoto H; Kawahara M; Iwami F; Kuba M; Furuse K; Tamura T; Saijo N; Shimoyama M
    Jpn J Clin Oncol; 1998 Dec; 28(12):745-8. PubMed ID: 9879292
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High-dose VP-16-213 monotherapy for refractory germinal malignancies: a phase II study.
    Wolff SN; Johnson DH; Hainsworth JD; Greco FA
    J Clin Oncol; 1984 Apr; 2(4):271-4. PubMed ID: 6368760
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Phase II study of VP-16 in patients with primary bronchogenic carcinoma, with special reference to small cell carcinoma--a multi-institutional cooperative study].
    Kanda T; Oka M; Hara K; Koteda T; Ishizaki T; Ikebe A; Nakano M; Iwasaki H; Tsutsumi T; Okuno K
    Nihon Gan Chiryo Gakkai Shi; 1986 Feb; 21(1):12-8. PubMed ID: 3009666
    [No Abstract]   [Full Text] [Related]  

  • 49. VP-16-213. A phase II trial using a weekly schedule.
    Karp G; Antman K; Canellos G
    Cancer Clin Trials; 1981; 4(4):465-7. PubMed ID: 7318129
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Etoposide (VP-16-213) and cis-dichlorodiammineplatinum (DDP) in advanced breast carcinoma resistant to previous chemotherapy.
    Athanassiades P; Bacoyiannes H; Kontoyiannes D
    Chemioterapia; 1986 Apr; 5(2):125-7. PubMed ID: 3518965
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
    Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
    Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Podophyllotoxin derivative VP 16-213.
    Arnold AM
    Cancer Chemother Pharmacol; 1979; 3(2):71-80. PubMed ID: 389478
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Effects of oral etoposide in small cell carcinoma of the lung].
    Miyamoto H; Ito M; Araya Y; Takaoka K; Isobe H; Dosaka H; Kawakami Y; Shimizu T; Onodera S
    Gan To Kagaku Ryoho; 1984 Jun; 11(6):1244-7. PubMed ID: 6329103
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Randomized phase II study with VP-16-213 (etoposide) in the treatment of advanced breast cancer].
    Cavalli F; Jungi WF; Brunner KW
    Onkologie; 1981 Apr; 4(2):80-3. PubMed ID: 7022286
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multicenter Phase II trial of etoposide in refractory small cell lung cancer.
    Issell BF; Einhorn LH; Comis RL; Lawson RD; Baker LH; Harvey HA; Lanzotti VA; Wampler GL; Daniels JR; Anderson PN
    Cancer Treat Rep; 1985 Jan; 69(1):127-8. PubMed ID: 2981617
    [No Abstract]   [Full Text] [Related]  

  • 56. Cis-dichlorodiammine platinum (II) in advanced ovarian carcinoma.
    Stewart JF; Tattersall MH; Woods RL; Fox RM
    Med J Aust; 1979 Jun; 1(12):548-50. PubMed ID: 470725
    [TBL] [Abstract][Full Text] [Related]  

  • 57. First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer.
    Athanassiou AE; Bafaloukos D; Pectasides D; Dimitriadis M; Varthalitis I; Barbounis V
    Br J Cancer; 1989 Nov; 60(5):755-8. PubMed ID: 2803952
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP-16-213 (NSC 141540, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside).
    Hansen M; Hirsch F; Dombernowsky P; Hansen HH
    Cancer; 1977 Aug; 40(2):633-7. PubMed ID: 196736
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II study of etoposide (VP-16) in the treatment of advanced head and neck cancer.
    Grunberg SM; Felman IE; Gala KV; Johnson KB; Owens JC
    Am J Clin Oncol; 1985 Oct; 8(5):393-5. PubMed ID: 4061373
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Therapeutic experiences using the new podophyllotoxin derivative VP 16-213 in malignant human tumors].
    Jungi WF; Senn HJ; Beckmann C; Flury R; Frei P; Holdener E
    Schweiz Med Wochenschr; 1975 Oct; 105(42):1365-9. PubMed ID: 179137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.